Combo Immunotherapy Plus Liver Embolization Targets Metastatic Uveal Melanoma

Uveal melanoma is a rare but aggressive cancer of the eye's pigmented layer. Unlike cutaneous melanoma, it responds poorly to standard checkpoint immunotherapy, and liver metastases — which occur in up to 50% of patients — carry a particularly grim prognosis with median survival often under one year. Finding effective treatments for this population is a pressing unmet medical need.

This phase II trial investigated whether combining two established checkpoint inhibitors — ipilimumab (anti-CTLA-4) and nivolumab (anti-PD-1) — with hepatic immunoembolization could improve outcomes. Immunoembolization targets tumors directly in the liver by blocking their blood supply while simultaneously releasing immunostimulatory agents to provoke a local and potentially systemic anti-tumor immune response. The rationale is synergistic: local tumor cell death releases antigens that the systemically activated immune system, primed by checkpoint blockade, can then recognize and attack.

The trial was sponsored by the Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University and enrolled 14 participants diagnosed with stage IV uveal melanoma with confirmed liver involvement. The study ran from May 2018 through December 2024 and has been marked as completed.

Because only the registration abstract is available, specific efficacy outcomes — including response rates, progression-free survival, and overall survival — cannot be reported here. However, the study's completion with 14 enrollees suggests it reached its target and that results are forthcoming.

If published results show meaningful activity, this combination could represent a meaningful advance for a patient population with very few effective options. The approach of pairing local liver-directed therapy with systemic immunotherapy is increasingly explored across multiple tumor types and warrants close attention as full data emerge.